

1/8

FIG.1.





FIG.2.



2/8

FIG. 3.



CLINICAL PERFORMANCE OF FDP
NORMAL vs FIVE TYPES OF CANCER (n=50)

FIG. 4.

BREAST CANCER
FDP vs CA 15-3

09/424740

FIG. 5.

COLON CANCER
FDP vs CA 19-9 (n=22)




FIG. 6.

COLON CANCER
FDP vs CEA (n=28)




FIG. 7.






FIG. 8.



5/8

FIG. 9.

PROSTATE CANCER
FDP vs PSA

6/8

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11a.




FIG. 11b.




FIG. 11c.




Figure 11. Selectivity of the Onohe assay: (A) noncompetitive inhibition by fibrinogen fragment D; (B) double reciprocal plot for fibrinogen; and (C) double reciprocal plot for fibrinogen fragment E.